Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Xeligekimab in Adult Patients With Moderate to Severe Plaque Psoriasis: A Multicenter, Prospective, Real-World Study

NCT06802848 is registered in ClinicalTrials.gov with Chongqing Genrix Biopharmaceutical Co., Ltd as lead sponsor.

NCT NCT06802848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06802848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Xeligekimab in Adult Patients With Moderate to Severe Plaque Psoriasis: A Multicenter, Prospective, Real-World Study
Lead sponsor
Chongqing Genrix Biopharmaceutical Co., Ltd
Phase
Observational
Overall status
Not yet recruiting
Start date
January 30, 2025
Completion date
December 31, 2026
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genital psoriasis, nail psoriasis, palmoplantar psoriasis, plaque psoriasis, psoriatic arthritis, scalp psoriasis